Guillain–Barre Syndrome Treatment Market Size & Forecast
The global Guillain–Barre syndrome treatment market was valued at USD 0.78 billion in 2025 and is projected to reach USD 1.27 billion by 2035, growing at a CAGR of 5.0% during 2026–2035. The forecast covers medicines, plasma-exchange consumables and treatment-linked services directly used to manage acute Guillain–Barre syndrome (GBS). It excludes the broader revenue of intensive-care equipment, general rehabilitation services and immunoglobulin used for unrelated diseases.
GBS is a rare, rapidly progressive autoimmune neurological disorder in which the immune system attacks peripheral nerves. Weakness can advance within days, and severe cases require respiratory monitoring, mechanical ventilation and intensive care. The World Health Organization states that people of all ages can be affected, although incidence rises with age and is slightly higher among males. Most patients recover, but a proportion experience persistent weakness, fatigue, pain or life-threatening complications. This clinical pattern makes treatment timing more important than long-term prescription volume.
The present market is concentrated around intravenous immunoglobulin (IVIG) and plasma exchange. Both approaches modify the acute immune response and are accepted standards of care for patients who cannot walk independently or whose symptoms are progressing. Corticosteroids do not provide the same established benefit in GBS. Supportive management remains essential because autonomic instability, swallowing impairment, respiratory failure, thrombosis and hospital-acquired complications can determine outcomes even after immunotherapy begins.
Commercial development is entering a new phase. Plasma-derived IVIG remains the revenue anchor, but the pipeline now includes mechanism-specific therapies designed to interrupt complement-mediated nerve injury. Tanruprubart, formerly ANX005, has generated Phase III evidence from a 241-patient trial and is being evaluated further. A successful targeted launch would not simply add another product; it could change treatment sequencing, hospital protocols, health-economic assessment and the evidence expected from future entrants.
Key Highlights
- The market is forecast to rise from USD 0.78 billion in 2025 to USD 1.27 billion in 2035 at a 5.0% CAGR, supported by diagnosis, immunoglobulin availability and a developing targeted-therapy pipeline.
- IVIG held 69% of 2025 revenue because it can be delivered without specialized apheresis infrastructure and is widely embedded in acute neurology protocols.
- Hospitals accounted for 84% of treatment revenue, reflecting the need for neurological assessment, respiratory surveillance, infusion management and rapid escalation to intensive care.
- North America generated 42% of global revenue in 2025. The United States alone represented 36%, supported by high treatment prices, hospital access and concentrated rare-neurology research.
- Asia-Pacific held 24% and is projected to record the fastest regional growth through 2035 as neurological referral networks, insurance coverage and plasma-fractionation capacity expand.
- Adults aged 18–64 represented 57% of market revenue, while patients aged 65 years and older formed the fastest-growing age segment because incidence and severe-case risk increase with age.
- Targeted complement therapies represented less than 3% of 2025 commercial revenue because no disease-specific therapy had established broad routine use; their share could rise sharply after regulatory approval and reimbursement.
Market Dynamics
Earlier Recognition and Hospital Referral Support Treated-Patient Growth
GBS is a neurological emergency, yet its early symptoms can resemble musculoskeletal, infectious or other neurological conditions. Greater awareness of ascending weakness, sensory changes, reduced reflexes, cranial-nerve involvement and recent infection supports earlier referral. Electrodiagnostic testing and cerebrospinal-fluid assessment help establish the diagnosis, but clinicians may initiate therapy before every confirmatory feature is present when progression is rapid.
Improved recognition expands the treated population without requiring a change in underlying incidence. The commercial effect is strongest where emergency departments, neurologists, intensive-care teams, laboratories and hospital pharmacies follow a coordinated pathway. Delayed referral has the opposite effect: patients may arrive with respiratory compromise, raising total care cost while narrowing the window in which an immune-directed intervention can prevent further nerve injury.
Plasma Collection and Fractionation Capacity Shape IVIG Availability
IVIG supply depends on donor recruitment, plasma collection, fractionation, viral safety processes, quality release and cross-border distribution. Production takes months, so short-term demand spikes cannot be answered like conventional small-molecule demand. Suppliers with collection networks and fractionation capacity possess a structural advantage, while hospitals remain exposed to allocation rules and competing demand from primary immunodeficiency, CIDP, immune thrombocytopenia and other indications.
Capacity investment supports market growth by reducing missed or delayed courses. Kedrion disclosed plans to invest more than USD 260 million in over 40 new US plasma-collection centers, more than USD 60 million in manufacturing expansion in Melville, New York, and further funds for clinical work, digital infrastructure and commercialization. Although its newly approved QIVIGY indication is primary immunodeficiency rather than GBS, the investment strengthens the wider IVIG production system relevant to acute neurological supply.
Targeted Complement Inhibition Could Redefine Clinical Value
Existing therapies broadly remove or neutralize circulating immune factors. Targeted complement inhibition aims to block a defined part of the pathological cascade before additional nerve damage occurs. Annexon reported that a single tanruprubart infusion produced a statistically significant improvement on the GBS Disability Scale at week eight in its Phase III study. The company also reported earlier mobility and muscle-strength gains and durable functional outcomes.
Commercial uptake will depend on more than statistical significance. Hospital committees and payers will examine time to independent walking, ventilation duration, intensive-care days, long-term disability, safety, administration logistics and performance across GBS variants. Evidence showing fewer resource-intensive hospital days could support a premium price. Evidence limited to an intermediate score may face more demanding reimbursement negotiations.
High Acute-Care Cost Creates Access Inequality
GBS treatment is delivered under time pressure and often requires inpatient admission. IVIG acquisition costs, plasma-exchange sessions, apheresis staff, central-line management, intensive-care monitoring and rehabilitation can create a substantial episode cost. In countries with limited insurance protection, hospitals may ration IVIG, delay therapy or use plasma exchange when equipment and trained staff are available.
Access therefore differs by institution as much as by country. Tertiary hospitals can provide respiratory testing, electrodiagnostics, apheresis and intensive care in one pathway. Smaller hospitals may need to transfer patients, losing valuable time. Growth in the addressable market depends on referral speed, reimbursement and product availability rather than disease incidence alone.
Diagnostic Uncertainty and Rare-Disease Trial Execution Restrain Development
GBS includes demyelinating and axonal forms with different geographic patterns and recovery trajectories. Patients present at different stages, and rapid treatment can complicate placebo-controlled study design. Recruiting enough participants within a narrow intervention window is difficult. Trial sponsors must standardize disability assessment, baseline severity, ventilation status, electrophysiological subtype and use of rescue therapy across sites.
The rare, acute nature of GBS also limits conventional commercial forecasting. A company cannot depend on repeat monthly prescriptions from the same patient population. Launch planning must prioritize emergency treatment protocols, hospital stocking, rapid diagnostic education and inclusion in neurological guidelines.
Strategic Takeaways
- IVIG manufacturers can protect share through dependable allocation, multiple vial sizes, hospital contracting and evidence that supports rapid acute-neurology use; brand promotion alone has limited influence during a neurological emergency.
- A targeted therapy needs to demonstrate shorter ventilation, intensive-care or rehabilitation requirements alongside functional improvement to support premium reimbursement and protocol adoption.
- Treatment adoption will be concentrated in tertiary hospitals first because these centers combine neurology, intensive care, apheresis, respiratory testing and pharmacy governance.
- Asia-Pacific expansion depends on local plasma availability, fractionation investment and referral pathways; epidemiological need without product access does not convert into equivalent revenue.
- Manufacturers should plan supply around multi-indication immunoglobulin demand because GBS competes for the same plasma-derived capacity used by chronic immunological and neurological conditions.
- Commercial evidence should distinguish AIDP from axonal variants, since regional subtype differences can affect response patterns, recovery time and the relevance of trial results.
- Hospital education should focus on treatment-window recognition and transfer protocols because the interval between symptom progression and specialist care directly affects clinical and commercial utilization.
Market Segmentation Analysis
By Treatment Type
IVIG led the market with 69% of 2025 revenue. Its position reflects clinician familiarity, standardized dosing and availability in hospitals that do not operate apheresis units around the clock. Plasma exchange represented 23%. It remains clinically important and can be economically attractive in selected health systems, but its use requires equipment, replacement fluid, vascular access and specialist personnel. Supportive pharmacotherapy and treatment-linked products accounted for 6%, covering pain management, thrombosis prevention and complication management directly associated with the GBS episode. Investigational targeted biologics and named-patient access contributed less than 2% of commercial revenue in 2025.
By 2035, IVIG is expected to retain the largest category but decline to 58% of revenue if targeted complement therapies achieve approval and reimbursement. Plasma exchange is projected to account for 18%, supportive products 6% and targeted biologics 18%. This mix is a forecast of commercial treatment revenue, not a recommendation to replace established care before regulators and clinical guidelines evaluate the evidence.
By Route of Administration
Intravenous treatment represented 91% of 2025 revenue because both IVIG and hospital-delivered targeted candidates use infusion pathways. Procedure-based extracorporeal treatment accounted for 8%, largely through plasma exchange consumables and direct treatment services. Oral, enteral and other routes represented 1% and were used mainly for symptom and complication management rather than disease modification. The intravenous share is expected to remain above 85% through 2035 even as the product mix changes.
By Disease Variant
Acute inflammatory demyelinating polyneuropathy, or AIDP, generated 62% of 2025 revenue and remains the leading diagnosed form in North America and Europe. Acute motor axonal neuropathy accounted for 18%, with greater relevance in parts of Asia and Latin America. Acute motor-sensory axonal neuropathy represented 8%, Miller Fisher syndrome 7%, and pharyngeal-cervical-brachial and other uncommon variants together held 5%. These shares reflect treated-market revenue; variant frequency and treatment cost differ across healthcare systems.
By Patient Age Group
Adults aged 18–64 produced 57% of 2025 revenue. Patients aged 65 years and older accounted for 31%, supported by greater incidence and a higher probability of complex hospital management. Pediatric patients represented 12%. The geriatric segment is forecast to gain share through 2035 because population aging raises the number of patients at risk and older adults are more likely to need intensive monitoring, respiratory assistance and extended rehabilitation.
By End User
Hospitals held 84% of 2025 revenue. Within this segment, tertiary and academic medical centers captured the greatest value because they manage severe disease, ventilation and apheresis. Specialty neurology centers accounted for 9%, while rehabilitation facilities represented 5% of treatment-linked spending. Home-infusion and other settings held 2%. GBS differs from chronic immunoglobulin indications: sudden progression and autonomic or respiratory risk keep initial disease-modifying treatment centered in hospitals.
By Distribution Channel
Hospital pharmacies controlled 81% of 2025 product revenue, followed by specialty distributors and pharmacies with 14%. Direct procurement and other channels held 5%. Hospital buyers emphasize assured delivery, cold-chain performance, batch traceability, pharmacovigilance and the ability to supply a complete treatment course. Specialty distribution is expected to grow where manufacturers use limited networks for high-value targeted products, but emergency availability will remain a central purchasing requirement.
Regional and Country-Level Analysis
North America
North America accounted for 42% of the global market in 2025, equal to USD 327.6 million. The United States generated 36% of global revenue, or USD 280.8 million, while Canada held 4% and Mexico 2%. The region leads because of high IVIG utilization, established intensive-care and apheresis infrastructure, reimbursement for hospital treatment and strong rare-neurology research. More than 22,000 people are hospitalized with GBS annually across the United States and Europe, indicating a concentrated acute-care burden.
US growth through 2035 will be influenced by the regulatory path for targeted complement therapy, evidence required by hospital formulary committees and plasma-product supply. Canada benefits from universal hospital coverage but remains sensitive to plasma-product procurement and imported supply. Mexico presents a mixed market: leading private and public tertiary hospitals provide advanced care, while access outside major cities is less consistent.
Europe
Europe held 28% of 2025 revenue, or USD 218.4 million. Germany represented 6% of global sales, the United Kingdom 5%, France 5%, Italy 3%, Spain 3% and the rest of Europe 6%. Regional demand is supported by specialist neurology networks, established IVIG use and public reimbursement. Its main constraint is plasma dependence. European health systems continue to strengthen donor recruitment and procurement resilience because immunoglobulin availability affects several rare and chronic diseases at once.
Germany leads European value through its hospital base and access to plasma-derived therapies. The United Kingdom uses nationally governed commissioning and clinical guidance, creating a structured but evidence-sensitive market. France combines strong hospital neurology with domestic plasma-sector capabilities. Italy and Spain offer meaningful demand, although procurement cycles and regional budget differences can affect speed of access to premium therapies.
Asia-Pacific
Asia-Pacific accounted for 24% of 2025 revenue, or USD 187.2 million, and is forecast to record the highest regional CAGR. China held 8% of global revenue, Japan 6%, India 4%, South Korea 2%, Australia 2% and the remaining Asia-Pacific markets 2%. Growth is supported by greater neurological diagnosis, hospital investment, insurance expansion and local plasma-fractionation projects.
China combines a large patient pool with improving tertiary care, but product access and treatment affordability vary by province. Japan has high diagnostic capability, an aging population and structured reimbursement, making it a high-value market for clinically differentiated therapies. India offers a large clinical need but remains constrained by out-of-pocket expenditure, uneven intensive-care access and variable IVIG affordability. Australia and South Korea contribute smaller patient volumes but have advanced hospital systems and clearer pathways for high-evidence products.
South America
South America generated 4% of 2025 revenue, or USD 31.2 million. Brazil represented 2.5% of global value, Argentina 0.7% and other countries 0.8%. Brazil is the regional center for neurological referrals and plasma-exchange capability, but public-sector purchasing pressure and uneven access outside major cities limit treatment consistency. Currency volatility and imported-product dependence influence procurement across the region.
Middle East and Africa
The Middle East and Africa held 2% of global revenue, equal to USD 15.6 million. Gulf Cooperation Council countries accounted for 0.9%, South Africa 0.5% and the remaining markets 0.6%. Advanced hospitals in the Gulf can provide IVIG, apheresis and intensive care, while many lower-resource systems face diagnosis, supply and affordability barriers. Referral networks, pooled purchasing and reliable distributor coverage offer the clearest route to improved access.
Recent Developments
- In April 2025, Annexon presented expanded Phase III tanruprubart data at the American Academy of Neurology meeting. The 241-patient study met its primary endpoint, and the company reported rapid and durable gains across disability, mobility and muscle-strength measures. Annexon also introduced a professional GBS education campaign focused on earlier recognition and care.
- In September 2025, Kedrion Biopharma received US FDA approval for QIVIGY, a 10% IVIG for adults with primary humoral immunodeficiency. The approved indication is not GBS, but the program expands Kedrion’s IVIG portfolio and is linked to new plasma-collection and manufacturing investment that can strengthen overall immunoglobulin capacity.
- In 2025, global plasma-product companies continued investments in collection, fractionation and immunoglobulin output. These programs matter to GBS hospitals because IVIG availability is governed by the same long production cycle and donor network that supplies multiple approved indications.
- Clinical development also broadened beyond a single pivotal data set. A registered open-label FORWARD study is evaluating tanruprubart in participants with GBS, extending the evidence program around C1q inhibition. Further results will be important for regulatory review, safety characterization and use across patient subgroups.
Competitive Landscape
Competition has two layers. The established layer consists of plasma collectors, fractionators and hospital suppliers with global IVIG portfolios. Their advantage rests on donor access, fractionation yield, quality systems, regulatory approvals and reliable allocation. The emerging layer consists of biotechnology companies developing targeted immune therapies. These entrants compete on mechanism, speed of effect and functional recovery rather than on plasma scale.
The market is moderately concentrated because building a compliant plasma network and fractionation plant requires high capital investment and long regulatory lead times. Hospital purchasing is also conservative: neurologists and pharmacists need confidence that a full course will be available when a patient arrives. A targeted entrant can disrupt this structure, but it must build rapid distribution, clinical education and reimbursement alongside regulatory approval.
Key Players
CSL Behring; Grifols, S.A.; Takeda Pharmaceutical Company Limited; Octapharma AG; Kedrion Biopharma; Biotest AG; Bio Products Laboratory; LFB Group; China Biologic Products Holdings; Annexon, Inc.; argenx SE; Hansa Biopharma; Fresenius Medical Care; Haemonetics Corporation; and Terumo Blood and Cell Technologies.
CSL Behring
CSL Behring is a leading global plasma-therapy company with an extensive donor, collection, fractionation and distribution network. Privigen is its liquid IVIG brand used across approved immunological and neurological indications, with country-specific labels governing use. The company’s competitive relevance to GBS comes from immunoglobulin manufacturing scale and hospital relationships. CSL reported strong immunoglobulin demand in fiscal 2025 and continued to invest in plasma supply and production productivity. Its principal market strengths are global supply reach, physician familiarity and a broad rare-disease portfolio; its exposure is the capital intensity and long lead time inherent in plasma-derived manufacturing.
Grifols
Grifols operates across plasma collection, diagnostic solutions and plasma-derived medicines. Gamunex-C and Flebogamma DIF are central immunoglobulin products in its portfolio, although labeled indications vary by jurisdiction and GBS use may be off-label. Grifols competes through vertically integrated plasma sourcing, fractionation expertise and hospital distribution. Its strategic position depends on expanding collection productivity, improving manufacturing utilization and managing debt while protecting product availability. For the GBS market, the most important differentiator is dependable access to high-volume IVIG rather than a disease-specific claim.
Takeda Pharmaceutical Company
Takeda’s plasma-derived therapies business includes immunoglobulin products and manufacturing assets serving rare immunological and neurological diseases. The company has invested in plasma collection and fractionation capacity to answer sustained global demand. Its scale, established hospital access and experience with complex biologics make it an important supplier in the GBS treatment ecosystem. Takeda’s opportunity is to use supply reliability and medical education to retain acute-neurology demand. The principal challenge is balancing GBS requirements against larger approved indications competing for the same immunoglobulin inventory.
Annexon, Inc.
Annexon is developing tanruprubart, a monoclonal antibody designed to inhibit C1q at the start of the classical complement cascade. Unlike IVIG or plasma exchange, the candidate is intended as a mechanism-specific, single-infusion intervention during the acute disease phase. Phase III results reported a 2.4-fold greater likelihood of being in a better health state on the GBS Disability Scale at week eight versus placebo. Annexon’s competitive position rests on being an advanced targeted program in a market without a broadly established disease-specific drug. Regulatory acceptance, manufacturing readiness, launch financing, hospital stocking and health-economic evidence will determine its ability to convert clinical differentiation into revenue.
